THE Schedule of Pharmaceutical Benefits was updated yesterday and the Summary of Changes can be found online.
Additions include Humira (adalimumab) in different forms, Repatha (evolocumab), Lenvima (lenvatinib - PD yesterday), Actemra (tocilizumab), Jetrea (ocriplasmin) and the combination drug Bi Eligard CP (leuprorelin and bicalutimide).
As usual a large number of additional brands have been added, along with equivalence indicators.
Items exempt from Statutory Price Reductions are listed along with a utilisation and cost model workbook to accompany the PBAC Guidelines - pbs.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Dec 16